Targeting apoptosis pathways in cancer therapy
IM Ghobrial, TE Witzig, AA Adjei - CA: a cancer journal for …, 2005 - Wiley Online Library
Apoptosis, or programmed cell death, is a mechanism by which cells undergo death to
control cell proliferation or in response to DNA damage. The understanding of apoptosis has …
control cell proliferation or in response to DNA damage. The understanding of apoptosis has …
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus …
Multiple myeloma is a malignant plasma cell neoplasm that affects more than 20,000 people
each year and is the second most common hematologic malignancy. It is part of a spectrum …
each year and is the second most common hematologic malignancy. It is part of a spectrum …
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
MQ Lacy, A Dispenzieri, MA Gertz, PR Greipp… - Mayo Clinic …, 2006 - Elsevier
Bisphosphonates are effective in the prevention and treatment of bone disease in multiple
myeloma (MM). Osteonecrosis of the jaw is increasingly recognized as a serious …
myeloma (MM). Osteonecrosis of the jaw is increasingly recognized as a serious …
[HTML][HTML] Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
SS Neelapu, FL Locke, NL Bartlett… - … England Journal of …, 2017 - Mass Medical Soc
Background In a phase 1 trial, axicabtagene ciloleucel (axi-cel), an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …
chimeric antigen receptor (CAR) T-cell therapy, showed efficacy in patients with refractory …
Review of 1027 patients with newly diagnosed multiple myeloma
Objective To determine the clinical and laboratory features of newly diagnosed multiple
myeloma. Patients and Methods Records of all patients in whom multiple myeloma was …
myeloma. Patients and Methods Records of all patients in whom multiple myeloma was …
[HTML][HTML] Effective surgical adjuvant therapy for high-risk rectal carcinoma
JE Krook, CG Moertel, LL Gunderson… - … England Journal of …, 1991 - Mass Medical Soc
Background Radiation therapy as an adjunct to surgery for rectal cancer has been shown to
reduce local recurrence but has not improved survival. In a previous study, combined …
reduce local recurrence but has not improved survival. In a previous study, combined …
Randomized controlled trial of yttrium-90–labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory …
PURPOSE: Radioimmunotherapy combines biologic and radiolytic mechanisms to target
and destroy tumor cells, thus offering a needed therapeutic alternative for refractory non …
and destroy tumor cells, thus offering a needed therapeutic alternative for refractory non …
POEMS syndrome: definitions and long-term outcome: Presented in abstract form at the 41st annual meeting of the American Society of Hematology, New Orleans, LA …
The POEMS syndrome (coined to refer to polyneuropathy, organomegaly, endocrinopathy,
M protein, and skin changes) remains poorly understood. Ambiguity exists over the features …
M protein, and skin changes) remains poorly understood. Ambiguity exists over the features …
[HTML][HTML] A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine
Background Primary systemic amyloidosis is an uncommon disease characterized by the
accumulation in vital organs of a fibrillar protein consisting of monoclonal light chains …
accumulation in vital organs of a fibrillar protein consisting of monoclonal light chains …
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
PURPOSE: Rituximab is commonly used as a single agent or in combination therapy for non-
Hodgkin's lymphoma (NHL). Ibritumomab tiuxetan radioimmunotherapy targets the same …
Hodgkin's lymphoma (NHL). Ibritumomab tiuxetan radioimmunotherapy targets the same …